Taletrectinib Adipate

己二酸他雷替尼

Report date: 2026/05/20 20:02:01
NME

Base Information

Drug NameTaletrectinib Adipate
Drug Alias Name泰莱替尼Taletrectinib-adipatetaletrectinib adipate他雷替尼Taletrectinib +[13] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionProto-oncogene tyrosine-protein kinase ROS inhibitorsNerve growth factor receptor Trk-A inhibitorsNeurotrophic tyrosine kinase receptor type 2 inhibitors +[4] 
TargetsProto-oncogene tyrosine-protein kinase ROSNerve growth factor receptor Trk-ANeurotrophic tyrosine kinase receptor type 2 +[4] 
Therapy Area/IndicationsMetastatic breast cancerSolid tumoursCarcinoma, Non-Small-Cell Lung +[5] 
Global Approved IndicationsCarcinoma, Non-Small-Cell Lung
Approved Indications in ChinaCarcinoma, Non-Small-Cell Lung
Original Approved Country/TerritoryMainland China
Original Approved Date2024/12/17
Country/TerritoryCanadaUnited StatesPoland +[10] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesDaiichi Sankyo Co Ltd
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesAnHeart Therapeutics Co LtdGuardant Health IncNewG Lab Pharma Co Ltd +[7] 
Inactive CompaniesAsymchem Life Science (Tianjin) Co Ltd
Active IndicationsSolid tumoursCarcinoma, Non-Small-Cell Lung
Inactive IndicationsMetastatic breast cancerBreast NeoplasmsNeoplasms

Other Information

ATC CodeN/A
Related LinksDrugBankKEGG